Showing 3121-3130 of 7750 results for "".
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the&
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- DermWire’s Practical Guide to Assessing Quality of Life and Mood in Patients With Chronic Skin Diseaseshttps://practicaldermatology.com/news/dermwires-practical-guide-to-assessing-quality-of-life-and-mood-in-patients-with-chronic-skin-diseases/2461936/Psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and other dermatological conditions often go more than skin deep and can have profound effects on a patient's quality of life, mood, and mental health. This is the main takeaway from a panel discussion on the psy
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cellshttps://practicaldermatology.com/news/regenerative-medicine-in-action-turn-bios-era-technology-reprograms-skin-cells/2461930/Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla. ERA reprogramming tec